ADULT Updated: March 5, 2024

Regimen Reference Order – GAST – PACLitaxel + CARBOplatin (anal)

ARIA: GAST - [PACL + CARBO (anal)]

Planned Course: Every 28 days until progressive disease/unacceptable toxicity

Indication for Use: Anal Cancer; Advanced

CVAD: At Provider's Discretion

Proceed with treatment if:

Day 1

• ANC equal to or greater than 1.5 x $10^9/L$ AND Platelets equal to or greater than $100 \times 10^9/L$ Days 8 and 15

- ANC equal to or greater than 1.0 x $10^9/L$ AND Platelets equal to or greater than 75 x $10^9/L$
 - Contact Physician if parameters not met

SEQUENCE OF MEDICATION ADMINISTRATION

Pre-treatment Requirements			
Drug	Dose	CCMB Administration Guideline	
Not Applicable			

Treatment Regimen – GAST – PACLitaxel + CARBOplatin (anal) Establish primary solution 500 mL of: normal saline **CCMB Administration Guideline Dose** Drug Day 1 cetirizine 20 mg Orally 1 hour prior to PACLitaxel aprepitant 125 mg Orally 1 hour pre-chemotherapy ondansetron 16 mg Orally 30 minutes pre-chemotherapy dexamethasone IV in normal saline 50 mL over 15 minutes 1 hour prior to 20 mg **PACLitaxel** *Nursing Alert: PACLitaxel starts 1 hour after completion of dexamethasone infusion Wait 1 hour after completion of IV pre-medication(s) before starting PACLitaxel **PACLitaxel** 80 mg/m² IV in normal saline 250 mL over 1 hour, following the administration rates below: Administer at 100 mL/hour for 15 minutes, then Administer remaining volume over 45 minutes Use non-DEHP bags and non-DEHP administration sets with 0.2 or 0.22 micron filter *Nursing Alert: Gently invert bag 8 to 10 times immediately prior to administration of PACLitaxel to evenly distribute the drug

CARBOplatin	AUC 5 mg/mL.min; maximum dose 750 mg (see table below)	IV in D5W 250 mL over 30 minutes
Days 8 and 15		
cetirizine	20 mg	Orally 1 hour prior to PACLitaxel
dexamethasone	20 mg	IV in normal saline 50 mL over 15 minutes <u>1 hour</u> prior to PACLitaxel *Nursing Alert: PACLitaxel starts 1 hour after completion of dexamethasone infusion
Wait 1 hour after comp	pletion of IV pre-medicat	tion(s) before starting PACLitaxel
PACLitaxel	80 mg/m²	IV in normal saline 250 mL over 1 hour, following the administration rates below: • Administer at 100 mL/hour for 15 minutes, then • Administer remaining volume over 45 minutes Use non-DEHP bags and non-DEHP administration sets with 0.2 or 0.22 micron filter *Nursing Alert: Gently invert bag 8 to 10 times immediately prior
All doses will be autom	atically rounded that fall	to administration of PACLitaxel to evenly distribute the drug within CCMB Approved Dose Bands. See Dose Banding document

In the event of an infusion-related hypersensitivity reaction, refer to the 'Hypersensitivity Reaction Standing Order'

REQUIRED MONITORING

All Cycles

Day 1

- CBC, serum creatinine urea, electrolytes and liver enzymes as per Physician Orders
- Full vital signs (temperature, heart rate, respiratory rate, blood pressure and O2 saturation) at baseline and as clinically indicated
- No observation period is required after PACLitaxel administration. Patient can be discharged from treatment room if stable whether they had a reaction or not

Days 8 and 15

- CBC as per Physician Orders
- Full vital signs (temperature, heart rate, respiratory rate, blood pressure and O₂ saturation) at baseline and as clinically indicated
- No observation period is required after PACLitaxel administration. Patient can be discharged from treatment room if stable whether they had a reaction or not




Recommended Support Medications			
Drug	Dose	CCMB Administration Guideline	
aprepitant	80 mg	Orally once daily on Days 2 and 3	
dexamethasone	8 mg	Orally once daily on Days 2 and 3	
metoclopramide	10 – 20 mg	Orally every 4 hours as needed for nausea and vomiting	

DISCHARGE INSTRUCTIONS

- Patients should be instructed to contact their cancer team immediately if symptoms of hypersensitivity reactions occur after discharge
- Instruct patient to continue taking anti-emetic(s) at home
- Reinforce applicable safe handling precautions of medications, blood and body fluids for 48 hours after completion of chemotherapy

ADDITIONAL INFORMATION

- PACLitaxel may cause progressive, irreversible neuropathy
- CARBOplatin dose considerations:
 - o CCMB Gastrointestinal DSG uses actual body weight to calculate GFR
 - o CCMB Gastrointestinal DSG uses a maximum CARBOplatin dose of 750 mg for this regimen
 - If calculated CARBOplatin dose differs more than 10% from prescribed CARBOplatin dose, contact the prescriber



AUC = Area Under Curve

The estimated creatinine clearance is based on limited evidence. Sound clinical judgment and interpretation of the estimation are required, because the equation may not be appropriate for some patient populations (for example, acute renal failure).

